Literature DB >> 22571665

Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.

Radek Jorda1, Kamil Paruch, Vladimír Krystof.   

Abstract

Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clinical trials as a candidate drug for some oncological indications. Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies. This article reviews known roscovitine bioisosteres that have been prepared as CDK inhibitors using different core heterocycles. The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochemical activity - only six direct analogs containing different purine bioisosteres have been prepared and evaluated side by side with roscovitine. Only four types of bioisosteres have demonstrated improved biological properties, namely pyrazolo[ 1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571665     DOI: 10.2174/138161212800672804

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  12 in total

1.  Overexpression of Fbxo6 inactivates spindle checkpoint by interacting with Mad2 and BubR1.

Authors:  Han-Zhang Xu; Zhuo-Qun Wang; Hui-Zhuang Shan; Li Zhou; Li Yang; Hu Lei; Bin Liu; Ying-Li Wu
Journal:  Cell Cycle       Date:  2018-12-18       Impact factor: 4.534

2.  CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.

Authors:  C Delehouzé; K Godl; N Loaëc; C Bruyère; N Desban; N Oumata; H Galons; T I Roumeliotis; E G Giannopoulou; J Grenet; D Twitchell; J Lahti; N Mouchet; M-D Galibert; S D Garbis; L Meijer
Journal:  Oncogene       Date:  2013-12-09       Impact factor: 9.867

3.  Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.

Authors:  Mary E Law; Patrick E Corsino; Satya Narayan; Brian K Law
Journal:  Mol Pharmacol       Date:  2015-05-27       Impact factor: 4.436

4.  Cyclin dependent kinase 5 is required for the normal development of oligodendrocytes and myelin formation.

Authors:  Yan Yang; Haibo Wang; Jie Zhang; Fucheng Luo; Karl Herrup; James A Bibb; Richard Lu; Robert H Miller
Journal:  Dev Biol       Date:  2013-04-10       Impact factor: 3.582

5.  Two inhibitors of yeast plasma membrane ATPase 1 (ScPma1p): toward the development of novel antifungal therapies.

Authors:  Sabine Ottilie; Gregory M Goldgof; Andrea L Cheung; Jennifer L Walker; Edgar Vigil; Kenneth E Allen; Yevgeniya Antonova-Koch; Carolyn W Slayman; Yo Suzuki; Jacob D Durrant
Journal:  J Cheminform       Date:  2018-02-20       Impact factor: 5.514

6.  A Simple Isomerization of the Purine Scaffold of a Kinase Inhibitor, Roscovitine, Affords a Four- to Seven-Fold Enhancement of Its Affinity for Four CDKs. Could This Be Traced Back to Conjugation-Induced Stiffenings/Loosenings of Rotational Barriers?

Authors:  Krystel El Hage; Jean-Philip Piquemal; Nassima Oumata; Laurent Meijer; Hervé Galons; Nohad Gresh
Journal:  ACS Omega       Date:  2017-07-12

Review 7.  The La-Related Proteins, a Family with Connections to Cancer.

Authors:  Chara Stavraka; Sarah Blagden
Journal:  Biomolecules       Date:  2015-10-16

8.  Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases.

Authors:  Andrea Bistrović; Anja Harej; Petra Grbčić; Mirela Sedić; Sandra Kraljević Pavelić; Mario Cetina; Silvana Raić-Malić
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

9.  The KDM4A/KDM4C/NF-κB and WDR5 epigenetic cascade regulates the activation of B cells.

Authors:  Kuo-Hsuan Hung; Yong H Woo; I-Ying Lin; Chin-Hsiu Liu; Li-Chieh Wang; Hsin-Yu Chen; Bor-Luen Chiang; Kuo-I Lin
Journal:  Nucleic Acids Res       Date:  2018-06-20       Impact factor: 16.971

Review 10.  When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.

Authors:  Santosh R D'Mello
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.